VVUS VIVUS, Inc.

1.04
+0  (3%)
Previous Close 1.01
Open 1.01
Price To book 5.84
Market Cap 109.81M
Shares 105,583,000
Volume 885,637
Short Ratio 6.90
Av. Daily Volume 603,708

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 17762221
  2. CT ORDER - Confidential treatment order 17751972
  3. CT ORDER - Confidential treatment order 17745774
  4. 8-K - Current report 17714220
  5. CT ORDER - Confidential treatment order 17695727

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved July 17, 2012.
Qnexa
Obesity
Approved Apr 27 2012. sNDA label change also approved 17 Sept 2014
Avanafil
Erectile dysfunction

Latest News

  1. VIVUS Announces Date of 2017 First Quarter Business Update and Financial Results Teleconference
  2. VIVUS (VVUS) Down 14.1% Since Earnings Report: Can It Rebound?
  3. Orexigen Releases Q4 Results, Vivus Reacquires Stendra from Sanofi
  4. VIVUS to Regain Commercial Rights for Stendra from Sanofi
  5. Vivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi
  6. VIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi
  7. 7 Most Popular Diet Pills That Work Fast Without Exercise
  8. VIVUS, Inc. :VVUS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017
  9. Markets Rally Late to Close in the Green: Today's Research Reports on Immunomedics and VIVUS
  10. VIVUS (VVUS) Beats on Q4 Earnings, Revenues Increase Y/Y
  11. Edited Transcript of VVUS earnings conference call or presentation 8-Mar-17 9:30pm GMT
  12. Vivus posts 4Q profit
  13. VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results
  14. VIVUS Announces Date of 2016 Fourth Quarter Business Update and Financial Results Teleconference
  15. Biotech's Rally Shows No Signs of Slowing Down: Today's Reports on Eyegate Pharmaceuticals and VIVUS
  16. Top 5 Biotech Stocks for 2017
  17. VIVUS Licenses Rights to PAH Drugs from Selten Pharma
  18. VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH)
  19. Arena Pharmaceuticals Dumps Belviq Weight Loss Drug
  20. VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?